Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody

J Immunother. 2007 Jan;30(1):130. doi: 10.1097/01.cji.0000211334.06762.89.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Carcinoma, Renal Cell / therapy
  • Humans
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects*
  • Interleukin-2 / immunology
  • Intestinal Perforation / chemically induced*
  • Ipilimumab
  • Kidney Neoplasms / therapy
  • Melanoma / therapy

Substances

  • Antibodies, Monoclonal
  • Interleukin-2
  • Ipilimumab